메뉴 건너뛰기




Volumn 29, Issue 5, 2011, Pages 1029-1037

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Author keywords

Adenocarcinoma; Doxorubicin; Esophageal cancer; Gastric cancer; Gastroesophageal cancer; Resistance; SP1049C

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; POLOXAMER; SP 1049C; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

EID: 84855921796     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9399-1     Document Type: Article
Times cited : (261)

References (40)
  • 1
    • 0026028040 scopus 로고
    • Rising incidence of adenocarcinoma of the esophagus and gastric cardia
    • Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289
    • (1991) JAMA , vol.265 , pp. 1287-1289
    • Blot, W.J.1    Devesa, S.S.2    Kneller, R.W.3    Fraumeni Jr., J.F.4
  • 2
    • 0033853456 scopus 로고    scopus 로고
    • Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries
    • Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645-654
    • (2000) Int J Epidemiol , vol.29 , pp. 645-654
    • Botterweck, A.A.1    Schouten, L.J.2    Volovics, A.3    Dorant, E.4    Van Den Brandt, P.A.5
  • 3
    • 13744258445 scopus 로고    scopus 로고
    • The role of overdiagnosis and reclassi-fication in the marked increase of esophageal adenocarcinoma incidence
    • Pohl H, Welch HG (2005) The role of overdiagnosis and reclassi-fication in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142-146
    • (2005) J Natl Cancer Inst , vol.97 , pp. 142-146
    • Pohl, H.1    Welch, H.G.2
  • 4
    • 23044493202 scopus 로고    scopus 로고
    • Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications
    • Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199-211
    • (2005) Ann Intern Med , vol.143 , pp. 199-211
    • Hampel, H.1    Abraham, N.S.2    El-Serag, H.B.3
  • 5
    • 33744732468 scopus 로고    scopus 로고
    • Body mass index and adenocarcinomas of the esophagus or gastric cardia: A systematic review and meta-analysis
    • Kubo A, Corley DA (2006) Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15:872-878
    • (2006) Cancer Epidemiol Biomarkers Prev , vol.15 , pp. 872-878
    • Kubo, A.1    Corley, D.A.2
  • 6
    • 0033580405 scopus 로고    scopus 로고
    • Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma
    • Lagergren J, Bergström R, Lindgren A, Nyrén O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adeno-carcinoma. N Engl J Med 340:825-831
    • (1999) N Engl J Med , vol.340 , pp. 825-831
    • Lagergren, J.1    Bergström, R.2    Lindgren, A.3    Nyrén, O.4
  • 7
    • 34347374560 scopus 로고    scopus 로고
    • How do we improve outcomes for gastric cancer?
    • Yeoh KG (2007) How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol 22:970-972
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 970-972
    • Yeoh, K.G.1
  • 8
    • 0038457443 scopus 로고    scopus 로고
    • Temporal trends (1973-1997) in survival of patients with esopha-geal adenocarcinoma in the United States: A glimmer of hope?
    • Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973-1997) in survival of patients with esopha-geal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627-1633
    • (2003) Am J Gastroenterol , vol.98 , pp. 1627-1633
    • Eloubeidi, M.A.1    Mason, A.C.2    Desmond, R.A.3    El-Serag, H.B.4
  • 9
    • 76749145878 scopus 로고    scopus 로고
    • Cancer of the stomach
    • De Vita VT et al eds, 8th edn. Lippincott Williams and Wilkins, Philadelphia
    • Pisters WTP, Kelsen DP, Tepper JE (2008) Cancer of the stomach. In: De Vita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1043-1079
    • (2008) Cancer Principles and Practice of Oncology , pp. 1043-1079
    • Pisters, W.T.P.1    Kelsen, D.P.2    Tepper, J.E.3
  • 10
    • 84861532120 scopus 로고    scopus 로고
    • Cancer of the esophagus
    • De Vita VT et al eds, 8th edn. Lippincott Williams and Wilkins, Philadelphia
    • Posner MC, Minsky BD, Ilson DH (2008) Cancer of the esophagus. In: De Vita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 993-1042
    • (2008) Cancer Principles and Practice of Oncology , pp. 993-1042
    • Posner, M.C.1    Minsky, B.D.2    Ilson, D.H.3
  • 11
    • 33745547767 scopus 로고    scopus 로고
    • Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
    • Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
    • (2006) J Clin Oncol , vol.24 , pp. 2903-2909
    • Wagner, A.D.1    Grothe, W.2    Haerting, J.3
  • 12
    • 33847638137 scopus 로고    scopus 로고
    • Estimates of the cancer incidence and mortality in Europe in 2006
    • Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
    • (2007) Ann Oncol , vol.18 , pp. 581-592
    • Ferlay, J.1    Autier, P.2    Boniol, M.3
  • 13
    • 33750949065 scopus 로고    scopus 로고
    • Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group
    • Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997
    • (2006) J Clin Oncol , vol.24 , pp. 4991-4997
    • Van Cutsem, E.1    Moiseyenko, V.M.2    Tjulandin, S.3
  • 14
    • 8044236424 scopus 로고    scopus 로고
    • Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
    • Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
    • (1997) Ann Oncol , vol.8 , pp. 163-168
    • Glimelius, B.1    Ekstrom, K.2    Hoffman, K.3
  • 15
    • 42749101089 scopus 로고    scopus 로고
    • Chemotherapy for metastatic carcinoma of the esophagus and gastroesophageal junction
    • Homs MY, Gaast A, Siersema PD, et al (2006) Chemotherapy for metastatic carcinoma of the esophagus and gastroesophageal junction. Cochrane Database Syst Rev CD004063
    • (2006) Cochrane Database Syst Rev
    • Homs, M.Y.1    Gaast, A.2    Siersema, P.D.3
  • 16
    • 0037089690 scopus 로고    scopus 로고
    • Epirubicin, cisplatin, and fluorouracil in gastric and oesophageal cancer: A step ahead?
    • Ilson DH (2002) Epirubicin, cisplatin, and fluorouracil in gastric and oesophageal cancer: a step ahead? J Clin Oncol 20:1962-1964
    • (2002) J Clin Oncol , vol.20 , pp. 1962-1964
    • Ilson, D.H.1
  • 17
    • 0242475354 scopus 로고    scopus 로고
    • Esophageal cancer: New developments in systemic therapy
    • Ilson DH (2003) Esophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525-532
    • (2003) Cancer Treat Rev , vol.29 , pp. 525-532
    • Ilson, D.H.1
  • 18
    • 33748412621 scopus 로고    scopus 로고
    • Cancer of the gastroesophageal junction: Current therapy options
    • Ilson DH (2006) Cancer of the gastroesophageal junction: current therapy options. Curr Treat Options in Oncol 7:410-423
    • (2006) Curr Treat Options in Oncol , vol.7 , pp. 410-423
    • Ilson, D.H.1
  • 19
    • 34548292026 scopus 로고    scopus 로고
    • Docetaxel, cisplatin, and fluorouracil in gastric cancer: Does the punishment fit the crime?
    • Ilson DH (2007) Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25:3188-3190
    • (2007) J Clin Oncol , vol.25 , pp. 3188-3190
    • Ilson, D.H.1
  • 21
    • 33846629672 scopus 로고    scopus 로고
    • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarci-noma
    • Shah MA, Ramanathan RK, Ilson DH et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarci-noma. J Clin Oncol 24:5201-5206
    • (2006) J Clin Oncol , vol.24 , pp. 5201-5206
    • Shah, M.A.1    Ramanathan, R.K.2    Ilson, D.H.3
  • 22
    • 0742271770 scopus 로고    scopus 로고
    • Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced esophageal and gastric carcinoma
    • Assersohn L, Brown G, Cunningham D et al (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced esophageal and gastric carcinoma. Ann Oncol 15:64-69
    • (2004) Ann Oncol , vol.15 , pp. 64-69
    • Assersohn, L.1    Brown, G.2    Cunningham, D.3
  • 23
    • 34250787547 scopus 로고    scopus 로고
    • Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer
    • Barone C, Basso M, Schinzari G et al (2007) Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 10:104-111
    • (2007) Gastric Cancer , vol.10 , pp. 104-111
    • Barone, C.1    Basso, M.2    Schinzari, G.3
  • 24
    • 38049047178 scopus 로고    scopus 로고
    • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    • Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46
    • (2008) N Engl J Med , vol.358 , pp. 36-46
    • Cunningham, D.1    Starling, N.2    Rao, S.3
  • 25
    • 38349183886 scopus 로고    scopus 로고
    • Expert opinion on management of gastric and gastro-oesophageal junction adeno-carcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group
    • Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adeno-carcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182-194
    • (2008) Eur J Cancer , vol.44 , pp. 182-194
    • Van Cutsem, E.1    Van De Velde, C.2    Roth, A.3
  • 26
    • 34147214716 scopus 로고    scopus 로고
    • Multiple molecular mechanisms for multidrug resistance transporters
    • Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-757
    • (2007) Nature , vol.446 , pp. 749-757
    • Higgins, C.F.1
  • 27
    • 31844448665 scopus 로고    scopus 로고
    • The translocation mechanism of P-glycoprotein
    • Callaghan R, Ford RC, Kerr ID (2006) The translocation mechanism of P-glycoprotein. FEBS Lett 580:1056-1063
    • (2006) FEBS Lett , vol.580 , pp. 1056-1063
    • Callaghan, R.1    Ford, R.C.2    Kerr, I.D.3
  • 28
    • 0348025526 scopus 로고    scopus 로고
    • Poloxamers
    • Rowe RC, Sheskey P, Weller PJ eds, American Pharmaceutical Association, Washington, DC
    • Collet JH (2003) Poloxamers. In: Rowe RC, Sheskey P, Weller PJ (eds) Handbook of pharmaceutical excipients. American Pharmaceutical Association, Washington, DC, pp 447-450
    • (2003) Handbook of Pharmaceutical Excipients , pp. 447-450
    • Collet, J.H.1
  • 29
    • 0032867434 scopus 로고    scopus 로고
    • Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
    • Alakhov V, Klinski E, Li S et al (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B: Biointerfaces 16:113-134
    • (1999) Colloids Surf B: Biointerfaces , vol.16 , pp. 113-134
    • Alakhov, V.1    Klinski, E.2    Li, S.3
  • 30
    • 0035556313 scopus 로고    scopus 로고
    • Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
    • Batrakova EV, Li S, Elmquist WF et al (2001) Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 85:1987-1997
    • (2001) Br J Cancer , vol.85 , pp. 1987-1997
    • Batrakova, E.V.1    Li, S.2    Elmquist, W.F.3
  • 31
    • 0029765581 scopus 로고    scopus 로고
    • Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells
    • Venne A, Li S, Mandeville R et al (1996) Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626-3629
    • (1996) Cancer Res , vol.56 , pp. 3626-3629
    • Venne, A.1    Li, S.2    Mandeville, R.3
  • 32
    • 33646348476 scopus 로고    scopus 로고
    • Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85
    • Batrakova EV, Kelly DL, Li S et al (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 3:113-123
    • (2006) Mol Pharm , vol.3 , pp. 113-123
    • Batrakova, E.V.1    Kelly, D.L.2    Li, S.3
  • 33
    • 17744382615 scopus 로고    scopus 로고
    • Effect of pluronic P85 on ATPase activity of drug efflux transporters
    • Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV (2004) Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226-2233
    • (2004) Pharm Res , vol.21 , pp. 2226-2233
    • Batrakova, E.V.1    Li, S.2    Li, Y.3    Alakhov, V.Y.4    Kabanov, A.V.5
  • 34
    • 1942470679 scopus 로고    scopus 로고
    • Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
    • Danson S, Ferry D, Alakhov V et al (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085-2091
    • (2004) Br J Cancer , vol.90 , pp. 2085-2091
    • Danson, S.1    Ferry, D.2    Alakhov, V.3
  • 35
    • 50549174560 scopus 로고
    • The determination of the number of patients required in a preliminary and a follow-up trial of a new chemo-therapeutic agent
    • Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemo-therapeutic agent. J Chronic Dis 13:346-353
    • (1961) J Chronic Dis , vol.13 , pp. 346-353
    • Gehan, E.A.1
  • 36
    • 0032921628 scopus 로고    scopus 로고
    • Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial
    • Waters JS, Norman A, Cunningham D et al (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269-272
    • (1999) Br J Cancer , vol.80 , pp. 269-272
    • Waters, J.S.1    Norman, A.2    Cunningham, D.3
  • 37
    • 0031022803 scopus 로고    scopus 로고
    • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
    • Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267
    • (1997) J Clin Oncol , vol.15 , pp. 261-267
    • Webb, A.1    Cunningham, D.2    Scarffe, J.H.3
  • 38
    • 33846419807 scopus 로고    scopus 로고
    • How can we best use structural information on P-glycoprotein to design inhibitors?
    • McDevitt CA, Callaghan R (2007) How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113:429-441
    • (2007) Pharmacol Ther , vol.113 , pp. 429-441
    • McDevitt, C.A.1    Callaghan, R.2
  • 39
    • 33745736603 scopus 로고    scopus 로고
    • Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment
    • Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859-1876
    • (2006) Curr Med Chem , vol.13 , pp. 1859-1876
    • Pérez-Tomás, R.1
  • 40
    • 33745746815 scopus 로고    scopus 로고
    • Pharmacological strategies for overcoming multidrug resistance
    • Nobili S, Landini I, Giglioni B et al (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861-879
    • (2006) Curr Drug Targets , vol.7 , pp. 861-879
    • Nobili, S.1    Landini, I.2    Giglioni, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.